Anti-CD44 monoclonal antibody IM7
Alternative Names: Anti-CD44 monoclonal antibody IM7.8.1; IM7; IM7.8.1Latest Information Update: 31 Oct 2002
At a glance
- Originator Rush-Presbyterian-St. Lukes Medical Center
- Developer Hebrew University of Jerusalem; Imperial College of Science, Technology and Medicine; Rush-Presbyterian-St. Lukes Medical Center; Western General Hospital
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Nov 2000 No-Development-Reported for Multiple sclerosis in United Kingdom (Unknown route)
- 09 Nov 2000 No-Development-Reported for Multiple sclerosis in USA (Unknown route)
- 09 Nov 2000 Preclinical development for Rheumatoid arthritis in Israel (Unknown route)